Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013 Jul 15; 119(14):2611-9.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antimetabolites, Antineoplastic
Antineoplastic Agents
Aurora Kinase B
Aurora Kinases
Cytarabine
Drug Administration Schedule
Female
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute
Male
Neutropenia
Organophosphates
Quinazolines
Stomatitis
Treatment Outcome

authors with profiles

HAGOP M KANTARJIAN
ELIAS JOSEPH JABBOUR